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Clinical application of mesenchymal stem cells (MSCs) represents a potential novel therapy for currently
intractable deteriorating diseases or traumatic injuries, including myocardial infarction. However, the
molecular mechanisms of the therapeutic effects have not been precisely revealed. Herein, we report that
conditioned media (CM) from rat adipose tissue-derived MSCs (ASCs) protected adult cardiomyocytes
from oxygen/glucose deprivation (OGD)-induced cell death. We focused on furin/PCSK protease activity
in ASC-CM because many therapeutic factors of MSCs and soluble cardioprotective factors include the
PCSK cleavage site. We found that recombinant furin protected cardiomyocytes from OGD-induced cell
death. The ASC-CM had potent furin/PCSK protease activity and the cardioprotective effect of the CM
from ASCs in the OGD-assay was abolished by an inhibitor of the furin/PCSK-like enzyme. Microarray
analysis and Western blot analysis showed PCSK5A, the secreted type of PCSK5, is the most abundantly
secreted PCSK among 7 PCSK family members in ASC. Finally, knockdown of PCSK5A in ASCs decreased
both the furin/PCSK protease activity and cardioprotective activity in the CM. These ﬁndings indicate an
involvement of furin/PCSK-type protease(s) in the anti-ischemic activity of ASCs, and suggest a new
mechanism of the therapeutic effect of MSCs.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent advances in medical management have greatly im-
proved the survival rate of patients after myocardial infarction
(MI), but signiﬁcant challenges remain in preventing progressive
loss of cardiomyocytes and chronic heart failure [1]. Stem cell
therapy or stem cell transplantation has emerged as a promising
new therapeutic option to replenish cardiac cells or to improve
cardiac functions in damaged hearts after MI. Both non-clinical
and clinical studies showed that various types of cells applied after
MI could improve cardiac function and promote regeneration of
the injured heart [2–5]. Mesenchymal stem cells (MSCs) are most
widely used in those studies, as they are relatively easily prepared
in large amounts, and also compatible with both autologous and
heterologous applications [6]. MSCs are originally isolated from
bone marrow, but have also been identiﬁed in various tissues, such
as adipose tissue, dental pulp, and umbilical cord blood [2,6–9].
Although beneﬁcial effects of MSCs have been well demonstrated,B.V. This is an open access article u
ies, Daiichi Sankyo Co., Ltd.,
apan.
o.co.jp (H. Kobayashi).the molecular mechanisms of their therapeutic effects have not
been deﬁned precisely.
In rat and porcine MI models, it has been demonstrated that
the injection of MSCs increased the number of cardiomyocytes and
improved heart function in parallel with myogenesis and angio-
genesis [10,11]. As the protective effects were observed within a
few days, it was suggested that the MSCs themselves did not dif-
ferentiate into cardiomyocytes, but provided trophic effects for
existing cardiomyocytes through cell–cell interactions or paracrine
factors [12–14]. In fact, MSCs secrete a wide range of bioactive
molecules, and administration of the conditioned media (CM)
from MSC cultures to MI animal models could recapitulate ther-
apeutic efﬁcacy in those models [14]. Several known angiogenic or
growth promoting factors, such as VEGF, IGF-1, and TSG-6 have
been identiﬁed as MSC-derived cardioprotective factors, which
supports the notion that well-coordinated secretion of multiple
factors is the key mechanism of the MSC action [15,16].
Recently, we identiﬁed a numerous number of trophic factors
secreted from three different types of MSCs, bone marrow-derived
mesenchymal stem cells (BMSCs), adipose-derived mesenchymal
stem cells (ASCs), and dental pulp-derived mesenchymal stem
cells (DPSCs), by conducting comprehensive proteomic analysis ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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commonly secreted factors. Because the CM of all the 3 MSCs has
been known to show similar cardioprotective activities [13,17], it
could be expected that those MSCs protect cardiomyocytes in the
same fashion with identical trophic factors. In this context, the list
of commonly secreted factors could provide promising candidates
to identify factors which explain the protective activity against MI
commonly observed in MSCs. In this report, we tried to identify
the MI protection MSC-factor from within the list of commonly
secreted factors and show evidence that furin/PCSK-like enzyme
activity in the ASC-CM represents the anti-ischemic activity of
ASCs, and suggests a new mechanism of the therapeutic effect of
MSCs.2. Materials and methods
2.1. ASC-CM preparation
Adipose tissue was isolated from lateral epididymis region in 6-
to 8-week-old Wistar male rats (Charles River). All experimental
procedures were performed in accordance with the in-house
guidelines of the Institutional Animal Care and Use Committee of
Daiichi Sankyo Co., Ltd. After visible blood vessels were removed
from the adipose tissue, it was minced by scalpel and digested by
0.1% collagenase type I (Worthington) for 1 h at 37 °C. Isolated cells
were ﬁltered through a 70 mm cell strainer, washed by PBS, and
suspended at the concentration of 1.5106 cells/mL in αMEM (Life
Technologies) with 9%FBS (Life Technologies) and 1% Antibiotic-
Antimycotic (AA). Cells were cultured at 37 °C in a humidiﬁed at-
mosphere of 5% CO2 and 5% O2, and used for experiments after 3–6
passages. MSC surface markers were conﬁrmed by using a ﬂow
cytometer. The ASCs were positive for CD44, CD29 and CD90 and
negative for CD11b/c and CD45 (data not shown).
ASCs grown nearly conﬂuent were washed three times with
PBS and cultured for an additional three days in serum free αMEM
with 1% AA. The collected medium was ﬁltered by 0.22 mm ﬁlters
(Millipore) and was concentrated and replaced with glucose-free
DMEM (Life Technologies) containing 1% AA using Amicon Ultra
3 kDa centrifugal ﬁlter (Millipore).
2.2. Rat adult cardiomyocyte OGD assay
Rat adult cardiomyocytes were isolated as previously described
[18]. Male Sprague–Dawley rats (Charles River) were anesthetized
with intraperitoneal administration of Somnopentyl (Kyoritsu
Seiyaku Corporation) 1 mL/kg. The heart was quickly removed from
the chest, and perfused with the perfusion buffer (120 mM NaCl,
14.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4,
10 mM HEPES, 4.6 mM NaHCO3, 5.6 mM glucose, 10 mM HEPES,
10 mM 2,3-butanedione monoxim, 30 mM taurine, pH 7.4) for
5 min. The buffer was switched to the digestion buffer containing
1 mg/mL collagenase type II (Worthington) and 0.1 mg/mL protease
(Sigma), and digested for 10–15 min until the heart became swollen
and turned pale. The ventricles were removed and transferred into
8 mL of the stopping buffer containing 10% FBS in the perfusion
buffer, and the tissue was minced by scissors. The dispersed cardi-
omyocyte suspension was ﬁltered by a 100 mm cell strainer. The
isolated cardiomyocytes were washed by glucose-free DMEM, and
re-suspended in the oxygen- and glucose-free DMEM with 1% AA
(OGDmedium), in which oxygenwas eliminated by N2 gas bubbling
for 2 h. The cardiomyocytes were seeded at 90–100% conﬂuence in a
24-well culture plate coated with laminin (Sigma) 40 μg/mL, and
incubated in a low oxygen (1% O2) condition for 2 h before adding
the tested materials, ASC-CM, recombinant furin, and/or furin in-
hibitors. After four hours treatment with test materials, glucose wasadded to the media at 4.5 g/L ﬁnal concentration, and the cells were
incubated in the normoxia condition overnight. Cells were co-
stained with 1 mM calcein-AM (Life Technologies) and 1 mM EthD-
1 (Life Technologies), ﬁxed with 2% paraformaldehyde, and washed
by PBS. Images were analyzed by IN Cell Analyzer 6000 (GE
Healthcare) with IN Cell Developer Toolbox image analysis software.
The indices for counting living cardiomyocytes were: major axis/
minor axis 43, staining area 4100 μmm2, form factor o0.6
among calcein-AM positive cells, except for cells indicating EthD-1
signal density 4800. The number of living cardiomyocytes was
counted four times in 9 ﬁelds.
2.3. Microarray analysis
Total RNA of rat ASCs was extracted using RNeasy mini kit
(QIAGEN) according to the manufacturer’s protocol. Biotinylated
cRNA was synthesized using 3′ IVT Express Kit (Affymetrix) from
250 ng of total RNA. The biotinylated cRNA was fragmented and
hybridized to the GeneChip Rat Genome 230 2.0 Array. The array
was washed, stained, and scanned using the GeneChip Fluidics
Station 450 and GeneChip Scanner 3000 7G according to the
GeneChip Expression Analysis Technical Manual (http://www.affy
metrix.com/support/downloads/manuals/expression_analysis_
technical_manual.pdf).
2.4. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Total RNA of ASCs and rat hearts was extracted as described
above. cDNAwas synthesized with random hexamer primers using
a High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). Real-time PCR was run on the ABI Prism 7900 sequence
detection system with pre-designed primer sets (Applied Biosys-
tems). The expression levels of genes were normalized to Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) used as internal
control.
2.5. Antibody
Primary antibodies used were: rabbit polyclonal anti-PC1/3
(Cell signaling), goat polyclonal anti-PC2 (Santa Cruz biotechnol-
ogy), rabbit anti-PCSK5 (Proteintech), rabbit anti-PCSK6, and rab-
bit anti-furin (Abcam). Secondary antibodies, donkey anti-rabbit
IRDye 800CW and donkey anti-goat IRDye 800 CW, were obtained
from Li-COR.
2.6. Western blotting
Cultured ASCs were lysed with the cell lysis buffer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.1% TrtionX-100) containing pro-
tease inhibitor cocktail (Roche). ASC lysate, ASC-CM (10 μg), or rat
tissue protein (30 μg) were loaded onto NuPAGE Novex 4–12% Bis-
Tris Gels (Life Technologies). Separated proteins were blotted onto
a nitrocellulose membrane (Immobilon-FL; Millipore), which was
then blocked with Odyssey Blocking Buffer (Li-COR) for 30 min at
room temperature. The membrane was incubated with primary
antibodies (1 μg/mL) overnight at 4 °C, washed with Tris-buffered
saline containing 0.075% Tween 20 (TBST), and then incubated
with an appropriate ﬂuorescent secondary antibody (0.1 μg/mL)
for 1 h. The protein bands were detected by an Odyssey Infrared
Imaging System (Li-COR).
2.7. Furin/PCSK-like enzyme activity
Furin/PCSK-like enzyme activity in ASC-CM was assessed by
using a ﬂuorescent substrate t-Butyloxycarbonyl-L-arginyl-L-valyl-
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Arg-Arg-MCA), which was designed to assess furin/PCSK-like ac-
tivity. ASC-CM or recombinant furin (R&D Systems) and/or furin
inhibitor (ENZO Life Sciences) were added to 50 μM of the syn-
thetic substrate in assay buffer (50 mM Tris-HCl, 15 mM NaCl,
0.005% Brij35, 10 mM CaCl2). The enzyme reaction was performed
at 37 °C for 2 h, and liberated AMC was measured by excitation at
380 nm and emission at 460 nm.
2.8. RNA Interference
The siRNAs for PSCK5 and the control (Life Technologies) were
AUAACAUGCUGUACGUCUCUCCAGG and AUACCAACGUUCUGCAU-
GUCUCAGG, respectively. ASCs 1.5106 cells were plated in a
15 cm dish 18 h before siRNA transfection. Each siRNA at 20 nM
was transfected 2 times at 24 h-intervals using Lipofectamine
RNAiMAX (Life Technologies). Transfected cells were washed
3 times with PBS and cultured for 3 days in serum free αMEM
containing AA.
2.9. Statistical analysis
All statistical analyses were performed using SAS System Re-
lease 8.2 (SAS Institute Inc., Cary, NC, USA), and data were ex-
pressed as means with standard deviation (SD). The statisticalFig. 1. Rat ASC-CM protected against adult cardiomyocyte cell death induced by OGD. Ra
OGD, many living cardiomyocytes were positive for calcein-AM and negative for EthD-1
number of living cells (C). The number of living cardiomyocytes was counted four times
versus control. Bar¼500 mm.signiﬁcance of differences between groups was tested by Student’s
t-test or Dunnett's test.3. Results
3.1. The ASC-CM protects against OGD-induced cell death of adult
cardiomyocytes
Various regulatory functions of MSCs have been reported, in-
cluding anti-inﬂammation, immunosuppression, angiogenesis,
and tissue repair [6,16]. One of the most validated clinical bene-
ﬁcial effects of MSCs is protection against MI. Although the precise
mechanisms of the protective function of MSCs against MI have
not yet been elucidated, increasing evidence supports the notion
that the injected MSCs are recruited to the damaged tissues and
then produce various trophic factors to protect damaged cells from
cell death. We previously identiﬁed common trophic factors se-
creted from three different types of MSCs, BMSCs, ASCs, and DPSCs
[17]. We presumed that the protein list could provide candidate
proteins which could explain the trophic action of the MSCs and
also clues which would explain their various effects.
In order to identify such protective proteins from the list,
we ﬁrst prepared an in vitro assay method of oxygen and glu-
cose deprivation (OGD)-induced cell death that mimics thet adult cardiomyocytes were stained with calcein-AM and EthD-1 (A, B, C). Without
(A). OGD/reperfusion induced cell death (B), and ASC-CM treatment increased the
in 9 ﬁelds (D). Data are shown as the means7SD (N¼4); Student's t-test, *Po0.05
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primary cardiomyocytes. Cardiomyocyte-like cell lines such as
H9c2 or primary cultured neonatal cardiomyocytes are normally
used for reperfusion injury assays. However, these cell lines or
neonatal cardiomyocytes proliferate actively in culture and are
not suitable for the analysis of ischemic cell death since adult
cardiomyocytes do not proliferate. To overcome this issue, car-
diomyocytes from adult rats were used in our assay. Cardio-
myocytes isolated from adult rats were incubated in glucose-
free DMEM under 1% O2 (OGD condition) for 6 h, then re-
plenished with glucose (25 mM) and 20% O2 for overnight. The
OGD treatment induced a morphological change of isolated
cardiomyocytes from rod shape into round shape, subsequently
causing cell death, and mimicking the condition in MI (Fig. 1A,
B). The rat ASC-CM protected adult cardiomyocytes from OGD-
induced cell death (Fig. 1C). This result suggests that ASC se-
creted protein(s) could suppress ischemic cell death of
cardiomyocytes.
3.2. Furin/PCSK-like enzyme activity is protective against OGD-in-
duced cardiomyocyte cell death
Then, we screened the trophic factors which exert a protec-
tive effect in the OGD assay. Among 124 proteins commonly
produced from the three MSCs [17], we ﬁrst focused on growth
factors and cytokines. Recombinant proteins of Activin A (con-
sisting homodimer of inhibinβA), C1q and tumor necrosis factorFig. 2. Furin/PCSK-like enzyme activity provided the protective effects to cardiomyocytes
with recombinant furin increased cell viability (A), which was canceled by Furin inhibito
enzyme activity was measured as the amount of released AMC from the synthetic su
(ng/mL) using the standard curve generated by recombinant furin. Furin/PCSK-like enzy
the means 7 SD (N¼4); Student’s t-test for (B)(D), Dunnett's test for (A)(D), **Po0.01related protein 3 (C1qTNF3), serpin peptidase inhibitor, clade E
(SERPINE1), follistatin like 1 (FSTL1), and nephroblastoma
overexpressed (NOV) were evaluated. However, the single
treatment of these recombinant proteins did not suppress OGD-
induced cell death in our assay (data not shown). We assumed
that not a sole protein, but proteins which modulate functions
of various proteins could play roles in this process. According to
this idea, we focused on proteases. Furin is known to cleave
various secreted proteins in cells and regulates the function and
secretion of those proteins. Several cardioprotective factors such
as EGF, IGF, and GDF-15 possess furin cleavage sites [19,20]. We
noticed that the list of commonly secreted factors contains
PCSK5 and PCSK6 and decided to validate the possibility of
PCSKs playing important roles in the cardioprotective activity of
the ASC-CM. In order to evaluate whether furin/PCSK-like ac-
tivity is important to the cardioprotective activity of ASC-CM,
recombinant furin protein was tested in the OGD-assay. Re-
combinant furin protein was used since there were no com-
mercially available PCSK5 proteins and we were unable to pro-
duce the recombinant secreted form of PCSK5 protein. Re-
combinant furin dose-dependently suppressed myocardiocyte
cell death to the same extent as ASC-CM in the OGD-assay
(Fig. 2A). The protective activity of recombinant furin was
completely canceled by a furin inhibitor (Furin inhibitor II)
(Fig. 2B). Furthermore, the protective activity of ASC-CM was
also blocked by the furin inhibitor (Fig. 2C). The ASC-CM showed
potent furin/PCSK-like peptidase activity, which was inhibited. Live rat cardiomyocytes were counted by an IN Cell analyzer as in Fig. 1. Treatment
r II (FI-II) (B). FI-II also canceled the protective effect of ASC-CM (C). Furin/PCSK-like
bstrates Boc-Arg-Val-Arg-Arg-MCA. The activity was expressed as degraded furin
me activity of ASC-CM was inhibited by FI- II dose dependently. Data are shown as
.
Table 1
The mRNA expression of PCSK family genes in ASCs. Two biological replicates were analyzed by microarray. The scaling signal was compensated by global scaling that set
average signal intensity of the each array to a target signal of 500. Detection calls (P: presence or A: absence) and detection p-value were determined by microarray suite
software (Affymetrix).
Probe set Gene Title Gene ASC #1 ASC #2
Scale Detection Detection Scale Detection Detection
Symbol Signal calls p-value Signal calls p-value
1387247_at proprotein convertase Pcsk1 2.0 A 0.458 13.1 A 0.171
subtilisin/kexin type 1
1387155_at proprotein convertase Pcsk2 5.4 A 0.970 0.7 A 0.905
subtilisin/kexin type 2
1367778_at furin (paired basic amino acid cleaving enzyme) Furin 343.2 P 0.001 364.9 P 0.000
1387213_at proprotein convertase Pcsk4 90.9 P 0.014 99.4 P 0.019
subtilisin/kexin type 4
1392773_at proprotein convertase Pcsk5 1924.4 P 0.006 1742.9 P 0.003
subtilisin/kexin type 5
1387812_at proprotein convertase Pcsk6 715.8 P 0.000 747.4 P 0.000
subtilisin/kexin type 6
1367886_at proprotein convertase Pcsk7 230.7 P 0.030 206.3 P 0.030
subtilisin/kexin type 7
Y. Tachida et al. / Biochemistry and Biophysics Reports 7 (2016) 266–272270by the furin inhibitor dose dependently (Fig. 2D). These results
indicated that ACSs secreted active PCSKs in culture.
Taken together, these results strongly suggest that the secreted
furin/PCSK-like enzyme activity plays a critical role in the cardio-
protective activity of ASC-CM in the OGD condition.Fig. 3. The expression of PCSKs in ASCs. The expressions of PCSKs at the mRNA level we
gene expression in ASCs and rat hearts' left ventricles (control) were normalized to GAPD
test, *Po0.05, **Po0.01) (B). Total protein from cell lysates and conditioned media of AS
tissue was used as a positive control for PCSK1, PCSK2, furin and PCSK6, and rat brain tiss
PCSK5A and PCSK6 in the conditioned media were slightly smaller in size, possibly bec3.3. PCSK5A is the main component of cardioprotective activity of
ASC-CM
In order to identify the main source of secreted furin/PCSK-like
enzyme activity in the ASC-CM, we analyzed expression proﬁles ofre examined by qRT-PCR. Ct values of the genes of the PCSK family (A) and relative
H, and fold changes relative to control are shown as mean7SD (N¼3, Student's t-
Cs were loaded on each lane and subjected to Western blot analysis (C). Rat kidney
ue lysate was used as a positive control for PCSK5A and PCSK5B (PC lane). Note that
ause of the processing before secretion.
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least nine endoprotease enzymes [21]. Among them, seven PCSKs
cleave the same site downstream of unique paired basic amino
acids within the motif (R/K Xn R/K↓ downward arrow indicates the
cleavage site) and it has been reported that PCSK1, PCSK2, PCSK5
and PCSK6 are secretory types [22]. First, we evaluated the mRNA
expression of the seven PCSKs. Microarray analyses of ASCs re-
vealed that among the four secretory PCSKs, PCSK5 and PCSK6
showed high signal intensity (Table 1). Quantitative RT-PCR ana-
lysis also revealed that, in accordance with the microarray results,
PCSK5 and PCSK6 were highly expressed (Fig. 3A) The PCSK5 ex-
pression level of the ASCs was over 25-fold higher than that of in
rat hearts (Fig. 3B). We then conducted protein expression analysis
in the CM. In our previous comprehensive proteomic analysis by
LC-MS we conducted previously [17], both PCSK5 and PCSK6 were
identiﬁed. There are two forms of PCSK5, PCSK5A and PCSK5B
which are a secretory form and cytosolic form respectively [19].
Western blot analysis revealed that only PCSK5A existed in the CM,
and PCSK5B existed in the cell lysate (Fig. 3C). On the other hand,
the expression of PCSK6 in the CM was lower than that in the cell
lysate (Fig. 3C). PCSK1 and PCSK2, the other two secreted type of
PCSKs, and furin in either the cell lysate or the CM were not de-
tected. These results indicate that PCSK5 would be the main source
of the furin/PCSK-like activity in the ASC-CM. To conﬁrm the im-
portance of PCSK5 in the cardioprotective activity of the ASC-CM,
CM were prepared from PCSK5A knockdown ASCs and tested in
the OGD-assay. The siRNA against PCSK5A dramatically decreased
the PCSK5A protein (Fig. 4A) and the Furin/PCSK-like enzyme ac-
tivity (Fig. 4B), which were consistent with the decrease of mRNA
expression (data not shown). The PCSK5A KD-CM signiﬁcantly
decreased the protective effect against OGD–induced cardiomyo-
cyte cell death (Fig. 4C). Collectively, our results indicated thatFig. 4. PCSK5 mediated the effect of ASC-CM on cardiomyocytes. The expressions of PCS
from ASC treated by PCSK5 targeted siRNA (A, B). In parallel, the cardioprotective effect
Student's t-test.PCSK5A is one of the critical components of ASC-CM that mediates
anti-OGD activity for adult cardiomyocytes.4. Discussion
Previous studies have shown that the application of MSCs could
improve heart function after MI by promoting angiogenesis and/or
suppressing cardiomyocyte cell death [10,23,24]. The therapeutic
effect is more likely to be based on an indirect mechanism pro-
vided by MSCs, such as paracrine factors and/or cell–cell interac-
tions, rather than MSCs being a part of regenerated tissues after
differentiation into cardiomyocytes or endothelial cells by them-
selves. Two lines of evidence support this notion. First, almost all
engrafted MSCs rapidly disappear from the sites, and there is no
solid evidence that those MSCs reside long enough to contribute to
the improvement of heart functions [16,25]. Second, MSCs can
secrete a wide range of bioactive molecules and trophic factors
that stimulate myocyte differentiation and angiogenesis, and MSC-
CM actually demonstrated a similar efﬁcacy to MSCs themselves
[14]. Among these secretions are VEGF, IFG-1, and TSG-6 [14,16].
Although the importance of MSC trophic factors is gaining more
attention, not many factors have been clearly deﬁned to be able to
substitute for MSCs' functions. In this study, we have demon-
strated that furin/PCSK-like enzymes are important MSC trophic
factors aiding in adult cardiomyocytes' protection.
Furin/PCSK-like activity played a critical role in the adult cardi-
omyocyte protective activity of ASC-CM (Fig. 2C). A diversity of
biological functions is known as being attributable to furin/PCSK
family members. Furin, one of the most studied family members,
has been known to cleave various secreted proteins, including IGF-1,
EGF, TGF-β, Lefty, BMP10, MMPs, and ADAMs, and convert themK5 and furin/PCSK-like activity were signiﬁcantly reduced in conditioned medium
of ASC-CM was attenuated by PCSK5 knockdown (C). **Po0.01 versus Ctrl siRNA,
Y. Tachida et al. / Biochemistry and Biophysics Reports 7 (2016) 266–272272into active forms [22]. Furin cleaves proteins at the site after unique
paired basic amino acids within the motif (R/K Xn R/K↓, downward
arrow indicates the cleavage site), which is also recognized by
PCSK1, PCSK2, PCSK4, PCSK5, PACE4 and PCSK7. Therefore, the
factors known as furin substrates could also be cleaved by these
other PCSKs. Normally, furin cleaves its substitute within cell
(Trans-Golgi network, cell surface [21]). We conﬁrmed that furin/
PCSK5-like enzyme activity in the ASC-CM showed a cardiomyocyte
protective effect and cell-impermeable furin inhibitor blocked the
effect (Fig. 2C), suggesting that furin/PCSK5-like enzyme activity
exerts its effects outside of cells. It has been estimated that PCSK1,
PCSK2, PCSK5, and PCSK6 are secreted types of PCSK, and our re-
sults indicated that PCSK5 is the most abundant PCSK (Fig. 3A–C)
and would be the main source of PCSK activity in ASC-CM (Fig. 4B).
Therefore, among the seven PCSK family members, PCSK5 is the
most promising candidate. It is intriguing to speculate that the
furin/PCSK5-enzyme activity of PCSK5 also plays a critical role in
protecting cardiomyocytes in vivo and in a clinical setting. Further
analysis such as identiﬁcation of PCSK5 substrates and evaluation of
PCSK5's function in an in vivo MI model would be required.
Accumulating evidence suggests that MSCs exert therapeutic
effects through secreting a variety of bioactive molecules, which
prevent organ damage or cell death, and/or stimulate regeneration
of injured tissues. Our ﬁndings that indicate the importance of
secreted furin/PCSK5-like enzyme activity support this notion, and
further suggest an intriguing hypothesis that multiple molecules
secreted after ischemic injury can be cleaved and activated by
furin/PCSK-type protease(s) to give rise to endogenous molecules
important for tissue regeneration and recovery. This hypothesis
reasonably explains the various biological effects of MSCs that are
difﬁcult to accomplish by any one sole factor alone, but could be
accomplished by the combination of several factors. Adrenome-
dullin has been shown to have angiogenic and cardioprotective
effects in MI injury model by activating the PI3K and Akt pathways
[26]. As pro-adrenomedullin is a HIF1α target gene and induced in
hypoxic hearts, it is possible that pro-adrenomedullin is produced
by cardiomyocytes in the OGD-condition and is processed to active
adrenomedullin by furin or PCSKs in ASC-CM. Key molecules in the
anti-OGD activity in our system still remain to be determined, but
concerted multiple mediators might be necessary to produce the
full activity. Therefore, the therapeutic application of a furin/PCSK-
type enzyme, such as PCSK5, may be an alternative approach for
treating acute MI or chronic heart failure after MI.
We identiﬁed PCSK5A as the important protective factor in the
unique OGD-assay by taking advantage of comprehensive pro-
teomic analysis of different types of MSCs. Although further vali-
dation is needed to prove PCSK5A as key trophic factor in MSCs’
cardiomyocyte protection, focusing on the commonly secreted
factors would be a powerful and efﬁcient way to ﬁnd other pro-
mising candidates. Identiﬁcation of such trophic factors would
provide us with deep understanding of the mechanisms of MSC
functions and could lead to a complete substitution of the MSC
therapy with recombinant protein(s).Acknowledgments
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